Furthermore, we found that YBX1 expression remained stable in all (4/4) NSCLC patients with intrinsic resistance after gefitinib treatment using immunohistochemistry analysis (Fig. 4c, d). This evidence concerns the gene YBX1 and non-small cell lung carcinoma.